// App-Quantinova.ai

577 : The First In Vitro and In Vivo Assessment Of Anfibatide, a Novel Glycoprotein Ib Antagonist, In Mice and In a Phase I Human Clinical Trial

Researchers

Presenter

  • Yan Hou

Principal Investigators

  • Xi Lei

  • Benjamin Li

  • Jie Shen

  • Hui Zhou

  • Yiming Wang

  • Alexandra H. Marshall

  • Heyu Ni

  • Xiangrong Dai

  • Zhongqiang Yang

  • Fang Qian

  • Guohui Zhang

  • Zhengyu Xu

  • Jing Liu

  • Chaofan Liang

  • Yanan Zhao

Medical Centers

  • Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

  • Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, Toronto Platelet Immunobiology Group, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada

  • Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Department of Laboratory Medicine and Pathobiology, and Toronto Platelet Immunobiology Group, University of Toronto, Toronto, ON, Canada

  • St. Michaels Hospital

  • School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, Anhui, China

  • Gejishan Hospital of Wannan Medical College, Wuhu, China

  • Department of Laboratory Medicine, Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital

  • Toronto Platelet Immunobiology Group, Toronto, ON, Canada

  • Canadian Blood Services, Toronto, ON, Canada

Locations

  • Canada

  • China

Companies

  • Zhaoke Pharmaceutica

  • Lee's Pharmaceutical

Study Components

Therapeutic Area

  • Obstetrics/Gynecology

Disease

  • Venous thrombosis

  • Twin-reversed arterial perfusion

Biomarkers

  • Triiodothyronine receptor auxiliary protein

  • von Willebrand factor

  • Activated partial thromboplastin time

Drug/Treatment

  • Anfibatide

  • Fibrinogen (IV)

  • Hemostatic Solution

  • Evithrom

Outcome

  • N/A


Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim